• Founded: 2011
  • Location: Farmingdale, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin3
  • Therapy area: COVID-19
  • Drug types: INF, VAC, ONC
  • Lead product: CoviLiv
  • Product link:
  • Funding: $25M B Feb 2023; $20M Feb 2020; $2M A Jun 2015; $322K Dec 2014
  • Investors: Serum Institute of India Pvt. Ltd., Euclidean Capital, Adjuvant Capital

job board

Short description:

Live-attenuated vaccine design technology

Drug notes:

RSV CodaVax Clin1 RSV, Clin0 pediatric RSV; Universal Influenza CodaVax Clin1 influenza; CDX-DENV Clin0 Dengue; CDX-ZiKV Clin0 Zika; undisclosed Clin0 yellow fever; CodaLytic Clin0 breast cancer; CDX-Onc Clin0 solid tumors

Long description:

Codagenix is developing live-attenuated viral vaccines using codon deoptimization technology. Live-attenuated viral vaccines involve giving patients an engineered dose of the virus that have been modified to prevent severe infection, but still trigger antibody production giving the patient protection against future exposure. Codagenix is leveraging their proprietary synthetic biology-driven approach to design hundreds of genetic edits that attenuate viral activity. Key to their approach is codon deoptimization - a strategy that prevents production of viral proteins which the virus needs to replicate. With this approach, Codagenix can deliver solutions for infectious disease and cancer that have the immunity benefits of live-attenuated viruses and are safe and scalable.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy